Q3 2025 Pulse Biosciences Inc Earnings Call Transcript

Nov 5, 2025 / 09:30 PM GMT

Release Date Price: $16.27 (+1.31%)

Transcript 10-Q8-K

Key Points

Positve

Pulse Biosciences Inc (PLSE) has made significant progress in advancing its three market development programs, particularly in soft tissue ablation and cardiac surgery systems.
The company received FDA investigational device exemption approval for its impulse cardiac surgery system for atrial fibrillation, marking a significant regulatory milestone.
The EPulse vibrance percutaneous electrode system for soft tissue ablation has shown strong product market fit, with over 200 patients treated and positive outcomes reported.
Initial revenues were generated in Q3 2025, indicating early commercial traction for the company's products.
The company is engaged in multiple clinical studies, including the precise BTN study and European feasibility studies, which are progressing well and expected to provide robust clinical evidence for their technologies.

Negative

Total GAAP costs and expenses increased significantly by $6.8 million to $20.5 million, driven by organizational expansion and non-cash stock-based compensation.
The company reported a GAAP net loss of $19.4 million in Q3 2025, an increase from the $12.7 million loss in the prior year period.
Cash used in operating activities increased to $13 million, reflecting continued expense management challenges.
The company's revenue of $86,000 is relatively low, indicating that the commercial adoption of its products is still in the early stages.
There is uncertainty regarding the funding of the pivotal trial for the EPulse 360 catheter, as the company may need to fund it unilaterally without a strategic partner.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PLSE.OQ - Pulse Biosciences Inc
Q3 2025 Pulse Biosciences Inc Earnings Call
Nov 05, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and thank you for standing by. My name is Mark and I will be your conference operator today. At this time, I would like to welcome everyone to the polls Biosciences Q3 2025 earnings call.

All lines have been placed on mute to prevent any background noise.

After the speaker's remarks, there will be a question-and-answer session.

If you would like to ask a question during this time, see to press star, followed by the number one on your telephone keypad.

And to withdraw your question, press start one again.

Thank you.

Now I would like to turn the call over to Trip Taylor in investor relations. Please go ahead.

-----------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.